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Recent findings raise the possibility of PARP inhibitor therapy in colorectal cancers
(CRCs). However, the extent of PARP-1 protein expression in clinical specimens of
CRC is not known. Using immunohistochemistry we assessed PARP-1 protein ex-
pression in tissue microarrays of 151 CRCs and its association with the patient’s age,
sex, Astler-Coller stage, grade and site of the tumor. High PARP nuclear im-
munoreactivity was found in 68.2% (103/151) of all cases. In turn, 31.8% (48/151)
of tumors showed low PARP expression, including 9 (6%) PARP-1 negative CRCs.
There was a significant association of PARP-1 expression with the site of CRC and
Astler-Coller stage. A high PARP expression was noted in 79.1% of colon vs. 53.9%
of rectal tumors (p = 0.001). The mean PARP-1 score was 1.27 times higher in colon
vs. rectal cancers (p = 0.009) and it was higher in stage B2 vs. stage C of CRCs 
(p = 0.018). In conclusion, the level of PARP-1 protein nuclear expression is asso-
ciated with the tumor site and heterogeneous across clinical specimens of CRC, with
the majority of CRCs expressing a high level but minority – low or no PARP-1 
expression. These findings may have a clinical significance because the assessment
of PARP-1 expression in tumor samples may improve selection of patients with CRC
for PARP inhibitor therapy. 
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Introduction
Poly(ADP-ribose)polymerase-1 (PARP-1) is a nu-
clear enzyme activated by DNA breaks and engaged
in the repair of DNA single-strand breaks via base ex-
cision repair pathway (BER) as well as in regulation of
transcription and cell cycle [1]. PARP inhibitors dis-
rupt BER rendering this repair pathway inactive what
leads to increased levels of persisting single-strand
breaks, with DNA double strand breaks (DSB) upon
replication as the end result. Tumor cells with defects
in homologous recombination, such as BRCA1-asso-
ciated breast cancers, cannot repair DSBs, hence
PARP-1 inhibition results in synthetic lethality in
BRCA1 and BRCA2-deficient cell lines [2, 3]. Based
on these results and preclinical studies that followed,
clinical trials of PARP inhibitors in treatment of
BRCA1-associated and triple negative breast cancers
have been initiated [4, 5] although results have not al-
ways fulfilled the expectations [5]. One reason may be
that a certain percentage of BRCA1-associated cancers
and triple-negative breast cancers had a low expression
of or did not express nuclear PARP-1 protein [6, 7] so
lack of the target protein could influence the results.
PARP-1 may play an important role in carcinogenesis
of CRC [8, 9]. Based on preclinical studies which showed
that PARP inhibitors can enhance the radiosensitivi-
ty and synergize with chemotherapy in experimental
models of CRCs, several clinical trials have recently been
initiated with the use of four PARP inhibitors in pa-
tients with CRC (reviewed in [10]). The goal is to elu-
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cidate the significance of PARP inhibition as a way to
sensitize CRC to DNA damaging agents currently used
in treatment of CRC. Recently, a novel approach to
colon cancer therapy in which 5-fluorodeoxyuridine
(FdUrd) is combined with a small molecule PARP in-
hibitor has been suggested [11]. Such PARP in-
hibitors sensitized both mismatch repair proficient and
deficient colon cancer cell lines to FdUrd because BER
turned out to be a critical repair pathway when these
cells were exposed to FdUrd. These findings raise a pos-
sibility that therapies that combine FdUrd with
a PARP inhibitor may act against colon cancer cells de-
spite the fact that they do not have defects in homol-
ogous recombination [11]. Thus, in view of incoming
possibility of PARP inhibitor therapy in colorectal can-
cers (CRCs) it is important to reveal the range of ex-
pression of PARP protein in clinical samples of this can-
cer. However, little is known about PARP-1 protein
expression in CRC [8, 12], specifically the extent of
PARP protein expression in clinical specimens of
CRC is not known. On the other hand, it has been
pointed out that a low expression or lack of the target
protein could influence the interpretation of clinical tri-
als of PARP inhibitors [13].
The purpose of this report is to assess the expression
of PARP-1 protein in CRC and to explore its associa-
tion with several clinicopathological factors such as age
and sex of the patient, Astler-Coller stage of the dis-
ease, grade and site of the tumor. 
Material and methods
Patients
The study was based on tumor tissue from 151 un-
selected, consecutive patients who met the following
criteria: 1) had undergone a potentially curative col-
orectal resection for sporadic CRC (absence of relevant
family history at the time of admission to the hospi-
tal); 2) had no chemotherapy or radiotherapy prior to
the operation; 3) invasive adenocarcinoma Astler-Coller
B2 or C without involvement of resection margins was
diagnosed by histopathological examination; 4) distant
metastases at the time of operation were excluded. 
Tumor pathology and tissue microarray 
construction
Tumor tissue was fixed in buffered 10% formalin
and embedded in paraffin. Sections (4 μm thick) were
stained with hematoxylin and eosin for histopathological
diagnosis. A pathology review was conducted at the De-
partment of Pathology, Pomeranian Medical Univer-
sity in Szczecin by two pathologists (PD, WD) asso-
ciated with the study to confirm histological diagnosis
of the colorectal cancer type. Representative histological
slides were used for tissue microarray construction. Two
different regions of tumors in the area of outer inva-
sive margin of cancer with highest mitotic activity were
identified and marked on hematoxylin and eosin
stained sections. The corresponding areas on the tis-
sue paraffin blocks were cored and transferred to a re-
cipient master block using a Tissue Microarrayer
(Beeacher Instruments, Silver Spring, MD, USA). Each
core was 0.6 mm wide. The recipient block was cut and
sections were transferred to coated slides. One slide was
stained with hematoxylin and eosin and a subsequent
slide for immunohistochemistry.
Immunohistochemistry
Slides with TMs were deparaffinized, rehydrated, and
endogenous peroxidase activity was blocked. Slides were
immersed in pH 6.0 buffer and heat induced antigen re-
trieval was performed in a water bath at 98°C for 20 min.
Monoclonal anti-PARP-1 antibody (F-2, dilution 1 :
500; Santa Cruz Biotechnology, Santa Cruz, CA) was
used. Slides were incubated for 30 min and im-
munostained using the Dako EnVisionTM+ kit ac-
cording to the manufacturer’s instructions. The reac-
tion was developed with a diaminobenzidine substrate
– chromogen solution and slides were counterstained
with hematoxylin. Positive staining in stromal lym-
phocytes served as a built-in positive control. Appro-
priate positive and negative controls were run. Thus,
the immunohistochemical procedure for all TMs from
151 tumors was performed at the same time under iden-
tical conditions and with the use of the sensitive En-
visionTM+ visualization system. Detection methods us-
ing signal amplification with HRP-labeled polymer
(such as EnvisionTM+) have been shown to be more sen-
sitive than methods without such a layer of amplification
[14]. CRCs were labeled as proximal or distal in rela-
tion to the splenic flexure.
Scoring
Tumor cores were assessed by 3 observers (JH, AM, WD)
who were blinded to clinical and pathological data. In cas-
es of disagreement, the result was reached by consensus.
To assess the immunohistochemical expression of PARP-
1 we used the multiplicative quickscore method (QS) be-
cause it seems to be the most reliable and proved to be use-
ful and reproducible [15]. Both intensity (0-3) and pattern
(1-6) scores were assessed. Each intensity score was mul-
tiplied by its corresponding pattern score (1 = 0-4% of pos-
itive tumor cells; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%;
5 = 60-79%; 6 = 80-100%) to obtain the final QS. Nu-
clear PARP-1 expression was graded as low (QS: 0-9) or
high (QS: 10-18). In order to reach the QS, all tumor cells
in the core of the tissue microarray were counted.
Statistics
Since the distribution of QS values was significantly
different from normal distribution (Shapiro-Wilk
test), non-parametric tests were used for the analysis.
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Association of QS values with categorical variables was
analyzed with Mann-Whitney test. The association be-
tween the presence of high PARP nuclear im-
munoreactivity (QS > 9) and other categorical vari-
ables was analyzed with Fisher exact test. A multivariate
logistic regression model was used to find the inde-
pendent factors associated with high QS values. 
P < 0.05 was considered statistically significant.
STATISTICA version 10 (StatSoft Inc., Tulsa, OK.,
USA) was used for the statistical analysis.
Results 
The mean age of patients was 60.8 ± 10.0 years,
with a range of 34-83 years, and a median of 62 years.
Table I lists other clinicopathological characteristics of
151 tumors and patients.
There was a wide variation in PARP-1 protein ex-
pression in the CRCs. Immunohistochemical staining
with the PARP antibody revealed strong nuclear re-
action in tumor cells (Fig. 1A, C) in the majority of
CRCs. The remaining tumors exhibited a moderate or
low level of PARP-1 expression, or were PARP-1 neg-
ative (Fig. 1B, D). Figure 1 shows representative ex-
amples of PARP-1 positive and PARP-1 negative CRCs.
The percentage of PARP-1 positive tumor cells differed
among CRCs. In some CRCs there was also a variation
in intensity of PARP-1 protein expression among tu-
mor cells. The distribution of nuclear PARP quickscores
(QS) among 151 CRCs is shown in Fig. 2. PARP-1 im-
munoexpression, although of lower intensity, could also
be found in the nuclei of some lymphocytes and stro-
mal cells (Fig. 1A, C). 
High PARP nuclear immunoreactivity (QS > 9) was
found in 68.2% (103/151) of all cases. In turn,
31.8% (48/151) of tumors showed low PARP im-
munoreactivity (QS ≤ 9) including 9 (6%) CRCs with
no immunoreactivity. 
There was a statistically significant association be-
tween nuclear PARP-1 QS and the site of the CRC.
A high PARP expression was detected in a larger per-
centage of colon cancers (68/86; 79.1%) than rectal tu-
mors (35/65; 53.9%) (p = 0.001), i.e. it was 1.5 times
more frequent in colon than in rectal cancer. The mean
PARP-1 score was 1.27 times higher in colon vs. rec-
tal cancers (p = 0.009) (Table I). There was also a sta-
tistically significant association between nuclear PARP-
1 QS and Astler-Coller stage (mean PARP-1 QS in B2
vs. C = 13.0 ±5.4 vs. 10.6 ±6.3, p = 0.018). No oth-
er statistically significant associations between PARP-1
expression and clinicopathologic characteristics were
found. 
When QS >9 vs. ≤ 9 was used as the cut-off level,
univariate logistic regression analysis has shown that the
odds ratio (OR) of QS > 9 was 3.24 (95% CI: 1.58-6.64,
p = 0.001) for colon as compared with rectal tumors.
A multivariate logistic regression analysis adjusted for
age, sex, grade and Astler-Coller stage demonstrated that
the CRC site was the only independent parameter sig-
nificantly associated with PARP-1 expression (OR = 
=3.72, 95% CI: 1.75-7.90, p = 0.0006).
Discussion
The introduction of PARP inhibitors has become an
exciting novel approach to treatment of human can-
cers. However, despite significant progress in under-
standing the role of PARP-1 in DNA repair and oth-
er biological processes, the level and extent of PARP-1
protein expression in major tumor types, including CRC
has remained largely unknown and is currently in-
tensively investigated e.g. in breast cancer [7], ovari-
an cancer [16], hepatocellular cancer [17], pancreat-
ic cancer [18], melanoma [19], and glioblastoma [20].
Specifically it is not clear whether PARP-1 overex-
pression is a characteristic feature of particular tumors,
their subtypes or subpopulations of tumor cells with-
in a given tumor. This knowledge seems to be neces-
sary to properly assess the results of clinical trials in-
volving targeted therapy with PARP-1 inhibitors
[13]. However, little is known about the range of
PARP-1 protein expression in clinical specimens of CRC.
Positive immunohistochemical expression of PARP-1
was found in 97.7% (42/43) of CRCs [21], 82.1%
(23/28) of CRCs [12], and 58.3% (35/60) of colorec-
tal adenomas and pT1 CRCs (however, the exact per-
centage of CRCs that expressed PARP-1 protein was
not given in this report) [8]. An association between
PARP-1 protein expression and clinicopathological char-
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Table I. Mean PARP QS* in relation to clinicopathologi-
cal characteristics
PARAMETER N (%) MEAN ± SD P
sex
females 80 (53) 11.40 ±6.00 0.434
males 71 (47) 12.04 ±6.11
histological grade
G1 + G2 83 (56) 11.42 ±5.97 0.411
G3 + muc 65 (44) 12.05 ±6.04
astler-Coller stage
B2 68 (45) 13.02 ±5.43 0.018
C 83 (55) 10.61 ±6.34
site
colon 86 (57) 12.90 ±5.49 0.009
rectum 65 (43) 10.12 ±6.42
site**
distal 119 (79) 11.52 ±5.96 0.3478
proximal 32 (21) 12.34 ±6.40
*quickscore, **with regard to splenic flexure
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acteristics such as age and sex of the patient, Astler-
Coller stage of the disease, grade and site of the tumor
has not been studied to date. 
In this report we evaluated PARP-1 expression in
151 CRCs in order to provide detailed information on
PARP-1 protein expression in this cancer and at the
same time to broaden our still incomplete knowledge
about PARP expression in clinical specimens of human
primary cancers. We found that: 
• the majority of CRCs exhibited a high expression of
nuclear PARP-1 protein; 
• CRCs constitute a heterogeneous group of tumors
with respect to PARP-1 expression, with some tu-
mors expressing high and other cancers – lower lev-
els of this protein; 
• approximately 6% of CRCs did not exhibit PARP-1
protein expression, and altogether, 32% of all tumors
exhibited low PARP-1 protein expression. Low or no
PARP-1 protein expression may have important ther-
apeutic implications because such tumors may be re-
fractory to treatment with PARP inhibitors (due to
lack of the target protein) and therefore they may re-
quire different therapeutic approaches. Clinical be-
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Fig. 1. PARP-1 expression in colorectal cancers (immunohistochemical reaction with PARP-1 monoclonal antibody).
A and B. Two cores from a tissue microarray, one (A) with PARP-1 protein expression in nuclei of tumor cells, the other
(B) negative for PARP-1 protein (original magnification 100×). C and D. High magnification (400×) of boxed area
from A (strong nuclear PARP-1 expression) and B (PARP-1 negative tumor cells)
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Fig. 2. Distribution of quickscores (QS) of nuclear PARP-1
expression in 151 colorectal carcinomas
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havior including response to treatment of PARP-1 pro-
tein negative CRCs is currently unknown and requires
further studies. In this context it is of interest that
PARP-1–/– cells display enhanced genomic instabil-
ity including chromosome aberrations, both in the ab-
sence of and after DNA damage [22, 23]; 
• nuclear PARP-1 protein expression was signifi-
cantly associated with the tumor site (colon vs. rec-
tum) and Astler-Coller stage (B2 vs. C). 
We also noticed that expression of PARP-1 was sig-
nificantly increased in cancer cells as compared with
normal stromal cells. A similar phenomenon has been
reported in a small group of patients with CRCs [21].
A slightly elevated level of PARP-1 mRNA was also
found in a group of 26 colon cancers as compared to
normal colon mucosa [24]. 
Loss of PARP-1 activity following treatment with
PARP inhibitors may induce synthetic lethality of tu-
mor cells whose homologous recombination-dependent
DNA double strand breaks repair is impaired because
of mutations in BRCA1 or BRCA2 [2]. For example,
deficiency in DNA repair through homologous re-
combination, which is a characteristic feature of
BRCA1/2-associated tumors, has been exploited in
treatment of breast cancers with PARP-inhibitors. How-
ever, it seems that germline mutations are not neces-
sary to obtain the therapeutic effect because BRCA1-
non-related tumors may also constitute a potential
target for some PARP inhibitors [25]. Recently it has
been suggested that CRCs displaying microsatellite in-
stability and deficient in double strand break repair due
to mutation in MRE11 gene (which is involved in DNA
repair through homologous recombination) can show
a higher sensitivity to PARP-1 inhibition, i.e. they also
can exhibit a synthetic lethality phenomenon [26].
Therefore, PARP positive CRCs might also be sensi-
tive to such treatment. Another recent report suggests
that small molecule PARP inhibitors sensitize colon can-
cer cell lines to FdUrd irrespective of their mismatch
repair status [11]. This raises a possibility that thera-
pies that combine FdUrd with a PARP inhibitor may
act against colon cancer cells despite the fact that they
do not have defects in homologous recombination [11].
In view of those results the information on PARP pro-
tein expression in CRCs seems to be of utmost im-
portance for designing clinical trials with the use of
PARP inhibitors and proper interpretation of results.
In conclusion, we showed here for the first time that
the level of PARP-1 protein nuclear expression is as-
sociated with the site of CRC and is heterogeneous across
clinical specimens of CRC. We also showed that the
majority of CRCs expressed a high level of nuclear
PARP-1 protein but minority of tumors exhibited a low
level of PARP-1 protein expression. The findings seem
to indicate that a subset of patients with low or no
PARP-1 protein expression may not respond to PARP
inhibitor therapy or may benefit very little. Therefore,
we suggest that future clinical trials involving PARP-
1 inhibitors in CRC should take into account PARP pro-
tein expression in tumor cells. Clearly, further research
is needed on the association of PARP-1 protein ex-
pression with clinical outcome of patients with CRCs
treated with PARP inhibitors.
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